1063 patents
Page 2 of 54
Utility
Method of Purity Determination by Capillary Electrophoresis
7 Dec 23
This disclosure provides protein separation techniques using detergents that have alkyl chains longer than 12 carbon atoms, which improves protein separation during electrophoresis.
Jeff W BECKMAN, Qian GUAN
Filed: 25 May 23
Utility
Antibodies Against TIM3 and Uses Thereof
30 Nov 23
Provided herein are antibodies, or antigen-binding portions thereof, that bind to T-cell immunoglobulin and mucin-domain containing-3 (TIM3) protein.
Xiao Min SCHEBYE, Mark J. SELBY, Michelle Minhua HAN, Christine BEE, Andy X. DENG, Anan CHUNTHARAPAI, Brigitte DEVAUX, Huiming LI, Paul O. SHEPPARD, Alan J. KORMAN, Daniel F. ARDOUREL, Ekaterina DEYANOVA, Richard HUANG, Guodong CHEN, Michelle KUHNE, Hong-An TRUONG
Filed: 27 Feb 23
Reissue
Oxazolidinones as modulators of MGLUR5
28 Nov 23
Andrew P. Degnan, Hong Huang, Lawrence B. Snyder, Fukang Yang, Kevin W. Gillman, Michael Frederick Parker
Filed: 22 Sep 21
Utility
Substituted 4-amino-1H-imidazo[4,5-c]quinoline compounds and improved methods for their preparation
28 Nov 23
Improved methods and intermediates thereof for preparing substituted 4-amino-1H-imidazo[4,5-c]quinoline compounds are described.
Sha Lou, Adrian Ortiz, Christopher Robert Jamison, Eric M. Simmons
Filed: 22 Nov 22
Utility
NLRP3 modulators
28 Nov 23
This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt, and/or hydrate, and/or cocrystal, and/or drug combination of the compound) that modulate (e.g., agonizes or partially agonizes) NLRP3 that are useful, e.g., for treating a condition, disease or disorder in which an increase in NLRP3 signaling may correct a deficiency in innate immune activity (e.g., a condition, disease or disorder associated with an insufficient immune response) that contributes to the pathology and/or symptoms and/or progression of the condition, disease or disorder (e.g., cancer) in a subject (e.g., a human).
Gary D. Glick, Shomir Ghosh, William R. Roush, Edward James Olhava, Daniel O'Malley
Filed: 6 May 21
Utility
Antibodies to alpha-synuclein and uses thereof
28 Nov 23
Disclosed herein are anti-α-synuclein antibodies which preferentially bind to oligomeric α-synuclein over monomeric α-synuclein, therapeutic compositions comprising the antibodies, and methods of using the antibodies to treat synucleinopathies.
Michael K. Ahlijanian, Jere Ernest Meredith, Jr., Nino Devidze, John David Graef, Edward L. Halk
Filed: 19 Jan 21
Utility
Methods for Concentrating Proteins
23 Nov 23
Provided herein are optimized methods for concentrating large volumes of antibody feedstocks to generate concentrated drug substances by ultrafiltration in a batch-like mode using a fed-batch setup.
Jessica Joy HUNG, Melissa Ann HOLSTEIN, Shing Fung LAM, Sanchayita GHOSE
Filed: 4 Oct 21
Utility
Aminoimidazole FPR2 Agonists
23 Nov 23
Heidi Perez, James A. Johnson, Sunita V. Dewnani
Filed: 8 Oct 21
Utility
Dimeric Milla Immunomodulators
23 Nov 23
The present disclosure provides novel macrocyclic peptides which inhibit the PD-1/PD-L1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.
Tao WANG
Filed: 8 Oct 21
Utility
4-azaindole compounds
21 Nov 23
Alaric J. Dyckman, Dharmpal S. Dodd, Christopher P. Mussari, Trevor C. Sherwood, Brian K. Whiteley, John L. Gilmore, Sreekantha Ratna Kumar, Laxman Pasunoori, Pitani Veera Venkata Srinivas, Srinivasan Kunchithapatham Duraisamy, Subramanya Hegde, Rushith Kumar Anumula
Filed: 30 Apr 21
Utility
Macrocyclic Peptide Boronate Immunomodulators
16 Nov 23
The present disclosure provides novel macrocyclic peptides which inhibit the PD-1/PD-L1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.
Tao WANG
Filed: 1 Oct 21
Utility
Combination Therapy with Anti-pvrig Antibodies Formulations, Anti-tigit Antibodies, and ANTI-PD-1 Antibodies
16 Nov 23
The present invention is directed to combination treatments with anti-PVRIG antibodies, anti-TIGIT antibodies, and anti-PD-1 antibodies, in particular nivolumab, using stable liquid pharmaceutical formulations thereof.
Adeboye Henry ADEWOYE, MD, Inbal BARBIRO, Ilan VAKNIN, Eran OPHIR, Pierre FERRE
Filed: 30 Sep 21
Utility
Macrocyclic Immunomodulators
16 Nov 23
The present disclosure provides novel macrocyclic peptides which inhibit the PD-1/PD-L1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.
Tao WANG
Filed: 8 Oct 21
Utility
Fibronectin based scaffold domain proteins that bind to myostatin
14 Nov 23
The present invention relates to fibronectin-based scaffold domain proteins that bind to myostatin.
Sharon Cload, Linda Engle, Dasa Lipovsek, Malavi Madireddi, Ginger Chao Rakestraw, Joanna Swain, Wenjun Zhao, Hui Wei, Aaron P. Yamniuk, Vidhyashankar Ramamurthy, Alexander T. Kozhich, Martin J. Corbett, Stanley Richard Krystek, Jr.
Filed: 14 Feb 19
Utility
Bi-specific antigen-binding polypeptides
14 Nov 23
The present invention provides antigen-binding polypeptides, including bi-specific antigen-binding polypeptides, that specifically bind to a first and a second target antigen with high affinity.
Yan Chen, Richard W. Wagner, Keming Zhang, Pascale Richalet
Filed: 22 Jan 19
Utility
Polymorphs of BIS(FLUOROALKYL)-1,4-BENZODIAZEPINONE Compounds and Uses Thereof
9 Nov 23
Marta DABROS, Joshua ENGSTROM, Daniel Richard ROBERTS
Filed: 2 Sep 21
Utility
Immunostimulatory Agonistic Antibodies for Use In Treating Cancer
9 Nov 23
Provided herein are methods of treating cancer using agonistic antibodies that specifically bind to immunostimulatory receptors, wherein the antibodies are administered in an amount and/or frequency sufficient to achieve and/or maintain a receptor occupancy of less than about 80%, for example, a receptor occupancy of about 20% to about 80%.
Marie-Claude GAUDREAU, Chan GAO, Michael QUIGLEY, Praveen AANUR
Filed: 10 Mar 23
Utility
Synthesis of 1,2,5-TRI-O-BENZOYL-3-DIBENZYLAMINO-3-DEOXYRIBOSE As Intermediate for Producing 3'-AMINO-3'-DEOXYADENOSINE and 3'-AMINO-3'-DEOXYGUANOSINE and the Protected Derivatives Thereof
9 Nov 23
The invention generally relates to improved processes for the preparation of intermediates of a cyclic dinucleotide which is useful as a STING agonist.
Changxia Yuan, Michael Anthony Schmidt, Adrian Ortiz, Amanda J. Rogers, Jason J. Zhu, Zhongmin Xu, Miao Yu, Eric M. Simmons, Shulin Wu
Filed: 5 Feb 20
Utility
Methods for Increasing Productivity of Therapeutic Proteins
9 Nov 23
The present invention generally relates to a method of producing a therapeutic protein of interest secreted from host cells cultured in a bioreactor through adding a carboxypeptidase to the cell culture.
Jianlin XU, Shun ZHENG, Zeinab H Dawood
Filed: 21 Sep 21
Utility
Imaging methods using 18F-radiolabeled biologics
7 Nov 23
The invention relates to water soluble 18F-prosthetic groups and the synthesis and use of 18F-labeled biological molecules containing the 18F-prosthetic groups for imaging various processes within the body, for detecting the location of molecules associated with disease pathology, and for monitoring disease progression are disclosed.
David Donnelly, David K. Leung
Filed: 10 Nov 22